It is currently trading at $2.56 impressively higher than the 50 day moving average which is $2.11 and barely below the 200 day moving average of $2.63. The 50 day moving average was up $0.45 or +21.18% and the 200 day average went down by -2.62%. (NASDAQ:SNSS) shares saw heavy trading volume with 657K shares changing hands on Tuesday. Trading volume was up 82.78% over the stocks average daily volume.
Short traders are feeling a little more bullish recently considering the decrease in short interest. The company saw a fall in short interest from September 29, 2017 to October 13, 2017 of -12.95%. Short interest decreased 36,146 over that period. The days to cover decreased to 1.0 and the short interest percentage is 0.01% as of October 13.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has been the object of insider buying activity recently. Director Dayton Misfeldt disclosed the purchase of 400,000 shares of SNSS stock. The shares were bought on October 27th for an average price of $2.00. The Director now owns $60,912 of the stock per the Form 4 SEC filing.
Here are a few substantial investment firms who have updated their positions. Citadel Advisors LLC augmented its holdings by buying 12,743 shares an increase of 84.7% as of 03/31/2016. Citadel Advisors LLC owns 27,782 shares worth $15,000. The value of the position overall is up by 15.4%. Creative Planning bolstered its ownership by buying 5,000 shares an increase of 33.3% from 06/30/2017 to 09/30/2017. Creative Planning now controls 20,000 shares with a value of $39,000. The total value of its holdings decreased 4.9%.
In the latest earnings report the EPS was $-1.89 and is estimated to be $-1.61 for the current year with 23,513,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.38 with next year’s EPS projected to be $-1.39.
Sunesis Pharmaceuticals, Inc., launched on February 10, 1998, is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZOTM (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Business’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229..